<DOC>
	<DOCNO>NCT01301248</DOCNO>
	<brief_summary>To examine safety toxicity concurrent radiotherapy cisplatin addition cetuximab experimental treatment</brief_summary>
	<brief_title>Cisplatin Chemoradiation With Without Cetuximab Locoregionally Advanced Squamous Cell Carcinomas ( SCC ) Head Neck</brief_title>
	<detailed_description>Conventional radiotherapy ( 65-70 Gy , 1.8 Gy per day ) concurrently weekly cisplatin ( 40mg/m2 ) ( group A , n=25 ) weekly cisplatin ( 40mg/m2 ) weekly cetuximab 250mg/m2 , initial dose 400mg/m2 ) ( group B , n=25 ) apply ( 1:1 randomization ratio ) . Groups match age , sex , PS , disease site .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>histologically confirm HNSCC oral cavity , larynx , oropharynx hypopharynx ; age 18 year adequate liver ( SGOT , SGPT , ALP ≤ 3x normal ) kidney ( creatinine clearance ≥ 60ml/min heart ( arrythmias , heart failure ) bone marrow ( WBC ≥ 4,000/μL , granulocyte ≥ 1,500/μL , Hb ≥ 10g/dL , platelet ≥ 100,000/μL ) function ECOG performance status 0 1 stage III IVa b measurable lesion write informed consent prior radiotherapy chemotherapy concurrent active malignancy pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>locally advanced ,</keyword>
	<keyword>unresectable ,</keyword>
	<keyword>head neck squamous cell carcinoma ,</keyword>
	<keyword>stage III/IV</keyword>
</DOC>